MGX · NASDAQ
Metagenomi, Inc.
$0.77 +0.02 (+2.67%)
Company overview
Metagenomi, Inc. is a gene editing biotechnology company that develops therapeutics for patients using a metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on a new genome editing system for in vivo human therapeutic applications, a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene-edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer, and a collaboration and license agreement with Ionis Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $29.1M
- Employees
- 202
- Headquarters
- Emeryville
- Website
- metagenomi.co
- CEO
- Jian Irish
- Listed
- April 6, 2006
- P/E
- -0.33
- Dividend yield
- 0.00%
Company financials
- Revenue
- $22.3M
- Gross profit
- -$2.8M
- Operating income
- -$92.8M
- EBITDA
- -$85.1M
- Net income
- -$85.9M
- EPS
- -$2.30
- Total assets
- $197M
- Total debt
- $39.2M
- Gross margin
- -12.54%
- Net margin
- -384.61%
- Earnings yield
- -298.70%
No annual segmentation.
No geographic segmentation.
MGX
1D
NASDAQ
O0.75H0.84L0.72C0.75-0.01 (-0.66%)Vol28.66K
News